skip to content



These guidelines are not an exhaustive manual covering all aspects of outpatient care.  They are a summary of information covering points of information that we hope will help staff manage patients.  The clinical information included is neither exhaustive nor updated frequently hence, wherever possible, links to authoritative guidelines provided by specialist professional bodies have been used.  However, there is no such thing as a ‘standard’ or ‘average’ transplant recipient. Guidelines are there to support, not replace, experienced and considered medical opinion. 


Clinics are held on Monday, Wednesday & Friday mornings in OPD1 at the Royal Infirmary of Edinburgh (RIE).  NHS Lothian doctors also provide outreach clinics for patients attending the Borders General Hospital & St John’s Hospital.

Suggested schedule for outpatient appointments

  • Three per week for first two weeks after discharge
  • Weekly until week 8.
  • Alternate weeks until week 12-16 (depending on graft function).
  • Monthly until end of first six months.
  • Two - three monthly until end of first year.
  • Three- six monthly during year two and beyond if stable with satisfactory graft function. 

Clinic records and communication:

  • Ensure that medications, weight and blood pressure are kept up to date in the electronic patient record (EPR).
  • Create immediate entry in EPR for patients returning to clinic the same week, mindful that paper letters may not be ready in time for next visit. 
  • Urgent changes to medications should be communicated immediately to the patient and the GP if they are required to issue a prescription or perform monitoring. All changes to medications or doses must be updated in Patient electronic record at the time of the change.
  • Copy all clinic letters to patients unless they request otherwise. Encourage patient enrolment with Renal Patient View to avoid the necessity of copying all letters.
  • Think carefully about the other clinicians who also require copies of letters – e.g. home renal unit if from another Health Board, other hospital clinics – e.g. Diabetes, Cardiology etc.
  • Note the immunosuppression regime the patient is following clearly in problem lists – e.g. Standard protocol, higher risk protocol, Trial Protocol etc – with desired tacrolimus trough range where relevant.

Key actions post-transplant:

  • Remove stent – usually at 8 weeks
  • Stop co-trimoxazole – usually at 3 month
  • Adjust  Valganciclovir dose according to Cockcroft-Gault  Creatinine  Clearance
  • Stop Valganciclovir – usually at 6 months 
  • Order ‘Virology at 3 Months Post SOTx’ from the trak order set at 3 months. This tests for HIV, Hep B, Hep C & Hep E (PCR).

At every visit check for@

  • Graft dysfunction: rejection, infection, obstruction, ischaemia, toxic/metabolic injury
  • Infection
  • Malignancy
  • Metabolic Disease
  • Cardiovascular disease
  • Progressive graft failure requiring preparation for further dialysis/transplant

For useful information on commonly prescribed medications, please see the immunosuppression appendix. This includes details of drug interactions with these agents. 


Specific issues to consider post-transplant:   


NODAT is a well-recognised phenomenon.  Risk factors/precipitants include medications – especially steroids, CNIs & sirolimus, previous impaired glucose tolerance and family history of diabetes.  An HbA1c >6.5% (IFCC>48) may be suggestive of NODAT.

It is recommended to screen for NODAT at the following intervals:

  • weekly for 4 weeks;
  • every 3 months for 1 year;
  • annually thereafter.

Where confirmed with either a diagnostic fasting blood sugar (>7 mmol/L) or with a positive glucose tolerance test (>11.1mmol/L  2 hours after 75g glucose), patients should be referred to a hospital diabetic clinic for further assessment and education.  Where sugar levels are not controlled with avoidance of high sugar food, oral hypoglycaemic agents may be started by the transplant clinic or – preferably – the General Practitioner or Diabetes clinic. 

Medications – especially immunosupressent drugs – should be reviewed in the Transplant clinic and consideration given to steroid withdrawal and/or CNI/sirolimus dose reduction.  Such decisions should be made on a case by case basis with a full assessment of risk of rejection, including discussion with Consultant H&I Clinical Scientists and review of previous episodes of rejection with Consultant Pathologist. 


Secondary hyperparathyroidism is common after transplantation and usually represents persistent disease in patients who have been on dialysis, often for years. The current evidence is that this may take over a year to settle down with good graft function and therefore it would be premature to recommend anything other than medical treatment for at least the first year. There is no current evidence in the literature as to what level of parathyroid hormone is acceptable in transplant patients.

Our current policy is that it should be normalised as far as possible using Alfacalcidol 0.25 - 1ug daily.           

All patients continuing with corticosteroids should be on Alfacalcidol 0.25 mcg/day, and calcium supplementation (up to 2 x 500mg tabs) daily or Calcichew D3Forte 2 tablets daily (if they have eGFR>30mls/min).

PTH should be checked at 1 month, 3 months and 6 months after transplant and thereafter at 6 monthly intervals. Patients uncontrolled (tertiary) hyperparathyroidism should be referred for surgery or considered for cinacalcet therapy if not appropriate for surgical parathyroidectomy.     


Hyperuricaemia and associated arthropathy (‘gout’) are common problems for renal transplant recipients.  Risk factors include reduced eGFR, diet rich in uratogenic nutrients and medications that increase plasma urate levels, including commonly used immunosuppressants and drugs to treat cardiovascular disease. 

Treatment of gout requires some modification from standard therapy in non-transplant patients.  These include:

  • Avoid NSAIDs if at all possible
  • Use new/increased dose of Prednisolone as first line treatment for attacks. Eg 15mg OD for 5 days (with a further 5 days if increasing the dose of xanthine oxidase inhibitor.

Note high risk of adverse interaction between azathioprine and allopurinol (or febuxostat)

  • Consider colchicine (0.5mg bd if tolerated) as alternative therapy for acute attacks but beware significant risk of diarrhoea, increasing risk of acute kidney injury, deranged tacrolimus levels or non-compliance. 
  • Some drugs – including diuretics and some beta-blockers can increase the risk of hyperuricaemia.  Conversely, LOSARTAN (but not other A2RBs or ACEis) decreases serum uric acid levels and can be used as an adjunctive treatment for gout. 


Transplant recipients have a very high relative risk of developing skin cancers – approximately 50x that of non-transplanted/non-immunosupressed comparable people.  The single greatest risk for skin cancer is UV damage to DNA, acquired through exposure to direct sunlight or artificial ‘tanning’ machines. 

Patients should be questioned about the appearance of new skin lesions at follow up outpatient consultations.  New lesions should be examined by an experienced doctor and, if features of concern are present, referral made to Dermatology Outpatient Dept, Lauriston Buildings, Edinburgh with the heading ‘Possible skin malignancy’ at the top of the letter. 


    Licensed under a Creative Commons LicenseCreative Commons Attribution 4.0 International License.

    K   Designed by beesign wien

    This page last modified 08.02.2018 14:35 by Emma Farrell. edren and edrep are produced by the Renal Unit at the Royal Infirmary of Edinburgh and the University of Edinburgh. CAUTIONS and Contact us.